Loading
A phase 1/2 trial of GIM-531 in melanoma, run by Georgiamune Inc, now recruiting.
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06425926 by Georgiamune Inc, with 117 participants planned, started 2024-05-09 and due to reach its primary completion in 2026-12. Interventions recorded: GIM-531 and Anti-PD-1 monoclonal antibody.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Georgiamune and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Melanoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/